KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Share-based Compensation (2016 - 2025)

Gilead Sciences (GILD) has disclosed Share-based Compensation for 17 consecutive years, with $230.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 3.6% year-over-year to $230.0 million, compared with a TTM value of $894.0 million through Dec 2025, up 7.07%, and an annual FY2025 reading of $894.0 million, up 7.07% over the prior year.
  • Share-based Compensation was $230.0 million for Q4 2025 at Gilead Sciences, roughly flat from $230.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $230.0 million in Q3 2025 and bottomed at $130.0 million in Q1 2022.
  • Average Share-based Compensation over 5 years is $188.4 million, with a median of $192.5 million recorded in 2023.
  • The sharpest move saw Share-based Compensation dropped 6.47% in 2022, then rose 26.92% in 2023.
  • Year by year, Share-based Compensation stood at $159.0 million in 2021, then increased by 9.43% to $174.0 million in 2022, then rose by 15.52% to $201.0 million in 2023, then grew by 10.45% to $222.0 million in 2024, then grew by 3.6% to $230.0 million in 2025.
  • Business Quant data shows Share-based Compensation for GILD at $230.0 million in Q4 2025, $230.0 million in Q3 2025, and $225.0 million in Q2 2025.